PGS9 A COST CONSEQUENCE ANALYSIS OF A NEW ENDOSCOPIC INJECTABLE TREATMENT VERSUS SURGERY IN PATIENTS WITH SEVERE GASTRO ESOPHAGEAL REFLUX DISEASE IN FRANCE